416 related articles for article (PubMed ID: 15342842)
1. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
Michaels LA; Gurian M; Hegyi T; Drachtman RA
Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
[TBL] [Abstract][Full Text] [Related]
2. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
[TBL] [Abstract][Full Text] [Related]
3. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
[TBL] [Abstract][Full Text] [Related]
4. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
5. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
6. Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?
Sanchez de Toledo J; Gunawardena S; Munoz R; Orr R; Berry D; Sonderman S; Krallman S; Shiderly D; Wang L; Wearden P; Morell VO; Chrysostomou C
Cardiol Young; 2010 Apr; 20(2):138-43. PubMed ID: 20199704
[TBL] [Abstract][Full Text] [Related]
7. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
Tetri S; Hakala J; Juvela S; Saloheimo P; Pyhtinen J; Rusanen H; Savolainen ER; Hillbom M
Thromb Res; 2008; 123(2):206-12. PubMed ID: 18420258
[TBL] [Abstract][Full Text] [Related]
8. Fluctuations of anti-Xa concentrations during maintenance enoxaparin therapy for neonatal thrombosis.
Lulic-Botica M; Rajpurkar M; Sabo C; Tutag-Lehr V; Natarajan G
Acta Paediatr; 2012 Apr; 101(4):e147-50. PubMed ID: 22211705
[TBL] [Abstract][Full Text] [Related]
9. Dosing and monitoring of enoxaparin (Low molecular weight heparin) therapy in children.
Ignjatovic V; Najid S; Newall F; Summerhayes R; Monagle P
Br J Haematol; 2010 Jun; 149(5):734-8. PubMed ID: 20346012
[TBL] [Abstract][Full Text] [Related]
10. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
[TBL] [Abstract][Full Text] [Related]
11. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
Corder A; Held K; Oschman A
Pediatr Blood Cancer; 2014 Jun; 61(6):1063-7. PubMed ID: 24375987
[TBL] [Abstract][Full Text] [Related]
12. Low-molecular-weight heparin in pediatric patients.
Sutor AH; Chan AK; Massicotte P
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():31-9. PubMed ID: 15085464
[TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
[TBL] [Abstract][Full Text] [Related]
14. A practical approach for bridging anticoagulation after mechanical heart valve replacement.
Steger V; Bail DH; Graf D; Walker T; Rittig K; Ziemer G
J Heart Valve Dis; 2008 May; 17(3):335-42. PubMed ID: 18592932
[TBL] [Abstract][Full Text] [Related]
15. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
Hammerstingl C; Omran H; Tripp C; Poetzsch B
Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
[TBL] [Abstract][Full Text] [Related]
16. Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin.
McLintock C; McCowan LM; North RA
BJOG; 2009 Nov; 116(12):1585-92. PubMed ID: 19681850
[TBL] [Abstract][Full Text] [Related]
17. Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.
Bui HT; Krisnaswami A; Le CU; Chan J; Shenoy BN
Am J Cardiol; 2009 Nov; 104(10):1429-33. PubMed ID: 19892063
[TBL] [Abstract][Full Text] [Related]
18. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.
Lin H; Faraklas I; Saffle J; Cochran A
J Trauma; 2011 Dec; 71(6):1557-61. PubMed ID: 22027887
[TBL] [Abstract][Full Text] [Related]
19. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial.
Veiga F; Escribá A; Maluenda MP; López Rubio M; Margalet I; Lezana A; Gallego J; Ribera JM
Thromb Haemost; 2000 Oct; 84(4):559-64. PubMed ID: 11057850
[TBL] [Abstract][Full Text] [Related]
20. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
